Fasedienol Nasal Spray: Vistagen Kicks Off Phase III Trial for Social Anxiety Disorder

Vistagen has taken a significant step forward in its PALISADE Phase III program with the enrollment of the first patient in the PALISADE-4 trial, marking another milestone in the development of fasedienol nasal spray for social anxiety disorder (SAD). This double-blind, placebo-controlled study aims to assess the efficacy, safety and tolerability of fasedienol as an acute treatment for SAD.